Reshaping the HIV treatment and prevention landscape

Driving growth of mid life cycle products Bexsero: Continued growth in market share gsk Benlysta: double digit growth 10 years since launch £m £m 750 750 700 700 650 650 600 600 550 550 500 500 450 450 400 400 350 350 300 300 250 250 200 200 150 150 100 100 50 50 0 0 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Source: GSK Annual Reports, all net sales at AER (Actual exchange rate) 35

View entire presentation